`
`ACRUX
`
`Acrux / About Acrux
`
`Board of
`Directors
`
`About Acrux
`
`Management
`Team
`
`Company
`Philosophy
`
`Partnering
`with us
`
`Contact Us
`
`Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and
`
`commercialising specialty and generic topical pharmaceuticals.
`
`Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully
`
`developed and commercialised through licensees a number of pharmaceutical products in
`
`the US and Europe using the Patchless PatchTM, a fast-drying and invisible topical
`
`application technology. Marketed products include Axiron®, Evamist~ and Lenzetto®. More
`
`recently, in addition to specialty products, Acrux has identified and initiated development of a
`
`range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing
`
`suite, clinical and commercial experience to bring more products to market. Acrux
`
`encourages collaboration and is well positioned to discuss partnering and product
`
`development.
`
`Products and technology
`
`Currently, we have three pharmaceutical products approved and marketed and are investing
`
`in research to develop further products to meet patients’ needs. Learn more about our
`
`commercialised products.
`
`Acrux’s proprietary technology is covered by broad, well-differentiated, issued
`patents. We continue to develop this technology, expanding the breadth of
`molecules which can be administered topically.
`
`Facilities and capabilities
`
`With onsite laboratories and a GMP manufacturing facility, we can oversee our products from
`
`early development through to clinical trials. We hold a TGA licence for the manufacture of
`
`transdermal and transmucosal products for clinical trials.
`
`Our development processes include, but are not limited to:
`
`http://www.acrux.com.au/about/[lO/27/2016 10:28:44 AM]
`
`ARGENTUM EX1045
`
`Page 1
`
`
`
`Abo~Acmx-Acmx
`
`¯ Analytical method development and validation
`
`¯ Container closure selection
`
`¯ Applicator or device development
`
`¯ Extractables and leachables testing
`
`¯ Stability testing
`
`¯ Manufacturing scale-up and technical transfer to commercial-scale facilities
`
`¯ Performing CMC activities, studies and reports for regulatory submissions
`
`Shareholders
`
`Acrux Limited is a listed entity on the ASX and is a Pooled Development Fund,
`registered under the Pooled Development Fund Act 1992.
`
`Under the Pooled Development Fund Act 1992, shareholders are entitled to
`concessionary tax treatment in Australia for income and capital gains derived in
`connection with their shareholding. Gains realised on the disposal of shares will
`
`not be included in an investors assessable income in Australia. An investor will
`not be entitled to any deduction or capital loss on the sale of shares. Unfranked
`dividends received by an Australian resident will be exempt from tax. Franked
`dividends will also be exempt from tax unless the shareholder elects to be taxed.
`
`An Australian corporate tax entity may credit its franking account (with franking
`credits attaching to a franked dividend), regardless of whether it has elected to
`treat the dividend as exempt or assessable income. Dividends paid to non-
`residents will not be subject to withholding tax. A shareholder or prospective
`shareholder should obtain their own tax advice rather than relying on this
`summary.
`
`ACRUX TIMELINE
`
`ii
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 2
`
`
`
`Abo~Acmx-Acmx
`
`First US patent granted
`
`Acrux listed on ASX
`
`(ACR:ASX)
`
`!
`
`Evamist® launched by KV
`
`Pharmaceutical
`
`Acrux initiates Axiron® Phase
`III clinical trial
`
`Axiron® launched by Eli Lilly
`
`J
`
`Veterinary licensed to Elanco
`
`globally (including
`Recuvyra®)
`
`Evamist® licensed to KV
`
`Pharmaceutical in US
`
`Acrux submits Axiron® NDA
`
`to FDA
`
`Axiron® licensed to Eli Lilly
`
`|
`
`Recuvyra® launched by
`
`Elanco
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 3
`
`
`
`Abo~Acmx-Acmx
`
`Evamist® licensed to Perrigo
`
`in US
`
`Estradiol licensed to Gedeon
`
`Richter; including for EU
`
`III
`
`". _ -:--
`
`Lenzetto® launched in Europe
`
`http://www.acrux.com.au/about/[10/27/2016 10:28:44 AM]
`
`Page 4
`
`